Skeletal muscle derived stem cells for myocardial repair

Husnain K. Haider, Lei Ye, Muhammad Ashraf

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Treatment of patients with heart failure secondary to myocardial infarction remains a therapeutic challenge. Extensive myocyte death in the heart and post-ischemic remodeling accentuate progressive expansion of the scar area and compromise left ventricular contractile function. The scarcity of resident stem cells in the heart and limited proliferative capacity of adult cardiomyocytes warrant novel strategies of outside intervention to supplement the inept intrinsic repair mechanism. Heart cell therapy using patient's own skeletal muscle derived myoblasts (SkMs) provides a relatively simple and inexpensive therapeutic option. Phase-I and II clinical trials supported by plethora of pre-clinical studies have shown the safety and effectiveness of SkMs engraftment in the treatment of infarcted heart. However, before widespread application of this approach in the clinical settings, there remain some fundamental issues including extensive donor cell death during acute phase after SkMs engraftment, failure of SkMs to adopt cardiac phenotype and transient ventricular arrhythmias subsequent to SkMs transplantation which require serious considerations. This review will provide profound analysis of merits and limitations of SkMs as the choice cells for heart cell therapy and will summarize the potential of genetic and pharmacological manipulation SkMs to enhance their therapeutic efficacy for myocardial repair. Present article also includes recent patent review coverage on this topic.

Original languageEnglish (US)
Pages (from-to)205-213
Number of pages9
JournalRecent Patents on Cardiovascular Drug Discovery
Volume2
Issue number3
DOIs
StatePublished - Nov 1 2007

Fingerprint

Skeletal Muscle
Stem Cells
Cell- and Tissue-Based Therapy
Therapeutics
Phase II Clinical Trials
Clinical Trials, Phase I
Myoblasts
Left Ventricular Function
Cardiac Myocytes
Muscle Cells
Cicatrix
Cardiac Arrhythmias
Cell Death
Heart Failure
Transplantation
Myocardial Infarction
Tissue Donors
Pharmacology
Phenotype
Safety

Keywords

  • Cardiac
  • Cells
  • Heart
  • Myocardium
  • Skeletal myoblasts

ASJC Scopus subject areas

  • Drug Discovery
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

Skeletal muscle derived stem cells for myocardial repair. / Haider, Husnain K.; Ye, Lei; Ashraf, Muhammad.

In: Recent Patents on Cardiovascular Drug Discovery, Vol. 2, No. 3, 01.11.2007, p. 205-213.

Research output: Contribution to journalReview article

@article{2bf969d2003b4baab524894cdf5c38b2,
title = "Skeletal muscle derived stem cells for myocardial repair",
abstract = "Treatment of patients with heart failure secondary to myocardial infarction remains a therapeutic challenge. Extensive myocyte death in the heart and post-ischemic remodeling accentuate progressive expansion of the scar area and compromise left ventricular contractile function. The scarcity of resident stem cells in the heart and limited proliferative capacity of adult cardiomyocytes warrant novel strategies of outside intervention to supplement the inept intrinsic repair mechanism. Heart cell therapy using patient's own skeletal muscle derived myoblasts (SkMs) provides a relatively simple and inexpensive therapeutic option. Phase-I and II clinical trials supported by plethora of pre-clinical studies have shown the safety and effectiveness of SkMs engraftment in the treatment of infarcted heart. However, before widespread application of this approach in the clinical settings, there remain some fundamental issues including extensive donor cell death during acute phase after SkMs engraftment, failure of SkMs to adopt cardiac phenotype and transient ventricular arrhythmias subsequent to SkMs transplantation which require serious considerations. This review will provide profound analysis of merits and limitations of SkMs as the choice cells for heart cell therapy and will summarize the potential of genetic and pharmacological manipulation SkMs to enhance their therapeutic efficacy for myocardial repair. Present article also includes recent patent review coverage on this topic.",
keywords = "Cardiac, Cells, Heart, Myocardium, Skeletal myoblasts",
author = "Haider, {Husnain K.} and Lei Ye and Muhammad Ashraf",
year = "2007",
month = "11",
day = "1",
doi = "10.2174/157489007782418955",
language = "English (US)",
volume = "2",
pages = "205--213",
journal = "Recent Patents on Cardiovascular Drug Discovery",
issn = "1574-8901",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Skeletal muscle derived stem cells for myocardial repair

AU - Haider, Husnain K.

AU - Ye, Lei

AU - Ashraf, Muhammad

PY - 2007/11/1

Y1 - 2007/11/1

N2 - Treatment of patients with heart failure secondary to myocardial infarction remains a therapeutic challenge. Extensive myocyte death in the heart and post-ischemic remodeling accentuate progressive expansion of the scar area and compromise left ventricular contractile function. The scarcity of resident stem cells in the heart and limited proliferative capacity of adult cardiomyocytes warrant novel strategies of outside intervention to supplement the inept intrinsic repair mechanism. Heart cell therapy using patient's own skeletal muscle derived myoblasts (SkMs) provides a relatively simple and inexpensive therapeutic option. Phase-I and II clinical trials supported by plethora of pre-clinical studies have shown the safety and effectiveness of SkMs engraftment in the treatment of infarcted heart. However, before widespread application of this approach in the clinical settings, there remain some fundamental issues including extensive donor cell death during acute phase after SkMs engraftment, failure of SkMs to adopt cardiac phenotype and transient ventricular arrhythmias subsequent to SkMs transplantation which require serious considerations. This review will provide profound analysis of merits and limitations of SkMs as the choice cells for heart cell therapy and will summarize the potential of genetic and pharmacological manipulation SkMs to enhance their therapeutic efficacy for myocardial repair. Present article also includes recent patent review coverage on this topic.

AB - Treatment of patients with heart failure secondary to myocardial infarction remains a therapeutic challenge. Extensive myocyte death in the heart and post-ischemic remodeling accentuate progressive expansion of the scar area and compromise left ventricular contractile function. The scarcity of resident stem cells in the heart and limited proliferative capacity of adult cardiomyocytes warrant novel strategies of outside intervention to supplement the inept intrinsic repair mechanism. Heart cell therapy using patient's own skeletal muscle derived myoblasts (SkMs) provides a relatively simple and inexpensive therapeutic option. Phase-I and II clinical trials supported by plethora of pre-clinical studies have shown the safety and effectiveness of SkMs engraftment in the treatment of infarcted heart. However, before widespread application of this approach in the clinical settings, there remain some fundamental issues including extensive donor cell death during acute phase after SkMs engraftment, failure of SkMs to adopt cardiac phenotype and transient ventricular arrhythmias subsequent to SkMs transplantation which require serious considerations. This review will provide profound analysis of merits and limitations of SkMs as the choice cells for heart cell therapy and will summarize the potential of genetic and pharmacological manipulation SkMs to enhance their therapeutic efficacy for myocardial repair. Present article also includes recent patent review coverage on this topic.

KW - Cardiac

KW - Cells

KW - Heart

KW - Myocardium

KW - Skeletal myoblasts

UR - http://www.scopus.com/inward/record.url?scp=36749003419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36749003419&partnerID=8YFLogxK

U2 - 10.2174/157489007782418955

DO - 10.2174/157489007782418955

M3 - Review article

C2 - 18221120

AN - SCOPUS:36749003419

VL - 2

SP - 205

EP - 213

JO - Recent Patents on Cardiovascular Drug Discovery

JF - Recent Patents on Cardiovascular Drug Discovery

SN - 1574-8901

IS - 3

ER -